☆ 4.5 Review

Multiple Myeloma

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)

期刊

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

卷 7, 期 9, 页码 908-942

出版社

HARBORSIDE PRESS

DOI: 10.6004/jnccn.2009.0061

关键词

multiple myeloma; Waldenstrom's monoclonal protein; C-reactive protein; combination chemotherapy; stem cell transplant; primary amyloidosis; cytogenetics; proteasome inhibitor; immunomodulatory drugs; bisphosphonates; supportive therapies; novel therapies

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma

Antoine Domenger, Daniela Ricci, Veronique Mayau, Laleh Majlessi, Christophe Marcireau, Gilles Dadaglio, Caroline Demangel

Summary: Multiple Myeloma is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy. Combining proteasome inhibitors and immunomodulators is effective in most patients, but some develop resistance. In this study, the researchers investigated the potential of Sec61 blockade as a treatment for refractory or relapsed Multiple Myeloma. They found that Sec61 blockade synergized with proteasome inhibitors and immunomodulators, even in drug-resistant cells. These results suggest that Sec61 blockers have potential as new anti-MM agents.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Review Hematology

Controversies in the use of new bone-modifying therapies in multiple myeloma

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos

Summary: Bone-modifying therapies, including zoledronic acid and denosumab, are essential for patients with multiple myeloma. Denosumab may offer a survival benefit for patients eligible for autologous transplantation and may be safer for those with renal impairment. Prophylactic measures for hypocalcaemia, renal toxicity, and osteonecrosis of the jaw are important considerations for all bone-modifying agents.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

Ola Landgren, Katja Weisel, Laura Rosinol, Cyrille Touzeau, Mehmet Turgut, Roman Hajek, Peter Mollee, Jin Seok Kim, Natalie Shu, Xuguang Hu, Chuang Li, Saad Z. Usmani

Summary: The subgroup analysis of CANDOR trial showed that carfilzomib with dexamethasone and daratumumab (KdD) had higher efficacy in treating relapsed/refractory multiple myeloma in adults, especially in patients with high-risk cytogenetics.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells

Maiko Matsushita, Sho Kashiwazaki, Satoshi Kamiko, Michio Kobori, Makoto Osada, Hisako Kunieda, Maki Hirao, Daiju Ichikawa, Yutaka Hattori

Summary: Several anti-cancer drugs have shown immunomodulatory effects, including immunogenic cell death (ICD) of cancer cells. ICD is a form of apoptosis caused by the release of damage-associated molecular patterns (DAMPs), uptake of cancer antigens by dendritic cells, and activation of acquired immunity against cancer cells. While ICD has been extensively studied in solid tumors, there is limited research on its occurrence in multiple myeloma (MM). This study demonstrates that proteasome inhibitors, such as carfilzomib, induce ICD in myeloma cells through a distinct unfolded protein response pathway compared to solid tumors. Additionally, it highlights the potential impact of ICD on MM patient survival, suggesting that ICD induced by proteasome inhibitors can enhance prognosis by not only exerting cytotoxic effects but also building a strong immune memory response in combination with other therapies like chimeric antigen receptor-T cell therapy.

PHARMACEUTICALS (2023)

添加到收藏夹

Article Immunology

Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling

Zeinab Waad Sadiq, Annamaria Brioli, Ruba Al-Abdulla, Gonca Cetin, Jacqueline Schuett, Hugo Murua Escobar, Elke Krueger, Frederic Ebstein

Summary: This study investigates the effects of protein homeostasis disruptors on multiple myeloma cells and shows that inhibition of protein de-ubiquitination can induce immunogenic cell death, suggesting a new therapeutic strategy.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Oncology

Inhibition of the L-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors

Monika K. Prelowska, Dawid Mehlich, M. Talha Ugurlu, Hanna Kedzierska, Aleksandra Cwiek, Artur Kosnik, Klaudia Kaminska, Anna A. Marusiak, Dominika Nowis

Summary: The combination of ASCT2 inhibitor and proteasome inhibitor enhances cytotoxic activity through inducing apoptosis and modulating autophagy.

CANCER LETTERS (2021)

添加到收藏夹

Article Cell Biology

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma

Minxia Liu, Yinyin Wang, Juho J. Miettinen, Romika Kumari, Muntasir Mamun Majumder, Ciara Tierney, Despina Bazou, Alun Parsons, Minna Suvela, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Paul Dowling, Peter O'Gorman, Jing Tang, Caroline A. Heckman

Summary: The S100 family members play a potential important role in the development of MM and resistance to established myeloma drugs, especially in the 1q21 chromosome region.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach

Rasmus R. Mikkelsen, Malthe P. Hundahl, Christopher K. Torp, Javier Rodriguez-Carrio, Mads Kjolby, Jens M. Bruun, Tue W. Kragstrup

Summary: This study assessed the efficacy of immunosuppressive drugs in patients with CVD or T2D. The results showed that immunosuppressive drugs targeting IL-1β have the potential to reduce CVD and T2D, validating in vitro and animal model findings. However, the potential treatment effects, adverse events, and cost-effectiveness of these drugs should be carefully considered.

EUROPEAN JOURNAL OF PHARMACOLOGY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity

Fengling Liu, Chunxi Liu, Qipeng Chai, Chunlong Zhao, Hongwei Meng, Xia Xue, Tso-pang Yao, Yingjie Zhang

Summary: In our previous research, a compound named 1 showed significant anti-tumor activity due to its HDAC inhibitory and NO-donating properties. Further study revealed that compound 1 could increase acetyl histones and acetyl & alpha;-tubulin levels by irreversibly inhibiting class I HDACs and HDAC6. Modification of compound 1 led to the development of compound 4, which selectively and irreversibly inhibited intracellular HDAC6 and exhibited improved therapeutic index compared to ACY-241.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

添加到收藏夹

Article Oncology

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression

Can Li, Erik B. Wendlandt, Benjamin Darbro, Hongwei Xu, Gregory S. Thomas, Guido Tricot, Fangping Chen, John D. Shaughnessy, Fenghuang Zhan

Summary: This study utilized gene expression profiling and genomic arrays to investigate molecular alterations in multiple myeloma (MM) and identified eight CNV events as possible MM drivers. By integrating gene expression and copy number variations data, eight unique MM subgroups were defined, each exhibiting common and unique protein network signatures that can be utilized for new therapeutic interventions. The study highlights the central role of 1q gains and the upregulated expression of certain genes as potential drivers of MM aggressiveness, presenting a novel approach to identify potential driver CNV events and areas for therapeutic intervention in MM.

CANCERS (2021)

添加到收藏夹

Article Hematology

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson

Summary: Rpn10 is highly expressed in MM cells and its inhibition can decrease MM cell viability by triggering protein accumulation, cell cycle arrest, and apoptosis. Additionally, inhibiting Rpn10 can increase autophagy, antigen presentation, and activate CD4(+) T and natural killer cells.

BLOOD (2023)

添加到收藏夹

Article Cell Biology

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition

Sara Petillo, Cristina Capuano, Rosa Molfetta, Cinzia Fionda, Abdelilah Mekhloufi, Chiara Pighi, Fabrizio Antonangeli, Alessandra Zingoni, Alessandra Soriani, Maria Teresa Petrucci, Ricciarda Galandrini, Rossella Paolini, Angela Santoni, Marco Cippitelli

Summary: In this study, it was found that inhibition of neddylation using MLN4924/Pevonedistat can increase the expression of NK cell-activating ligands on the plasma membrane of MM cells, leading to enhanced NK cell degranulation. This suggests that modulation of neddylation can sensitize MM to NK cell killing, providing new insights into the anticancer activity of neddylation inhibition.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Review Oncology

Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

Danai Dima, Fauzia Ullah, Sandra Mazzoni, Louis Williams, Beth Faiman, Austin Kurkowski, Chakra Chaulagain, Shahzad Raza, Christy Samaras, Jason Valent, Jack Khouri, Faiz Anwer

Summary: Multiple myeloma is a common blood malignancy with limited cure. Recent advances in advanced therapies have improved survival and quality of life, but relapse and drug resistance remain major challenges. This review focuses on the treatment of relapsed/refractory multiple myeloma, highlighting novel modalities like CAR-T cell therapy and bispecific antibodies. Factors like relapse characteristics and patient-related parameters are discussed in relation to drug combination and cellular therapy selection, with the aim of guiding therapeutic decision-making.

CANCERS (2023)

添加到收藏夹

Article Oncology

The mevalonate pathway is an actionable vulnerability oft(4;14)-positive multiple myeloma

Joseph Longo, Petr Smirnov, Zhihua Li, Emily Branchard, Jenna E. van Leeuwen, Jonathan D. Licht, Benjamin Haibe-Kains, David W. Andrews, Jonathan J. Keats, Trevor J. Pugh, Suzanne Trudel, Linda Z. Penn

Summary: This study revealed that t(4;14)-positive multiple myeloma cells depend on the mevalonate (MVA) pathway for survival and are sensitive to statin treatment. Statins induce apoptosis in t(4;14)-positive cells and synergize with bortezomib to enhance anti-tumor activity.

LEUKEMIA (2021)

添加到收藏夹

Article Medicine, General & Internal

The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients

Joanna Barankiewicz, Anna Szumera-Cieckiewicz, Aleksander Salomon-Perzynski, Paulina Wieszczy, Agata Malenda, Filip Garbicz, Monika Prochorec-Sobieszek, Irena Misiewicz-Krzeminska, Przemyslaw Juszczynski, Ewa Lech-Maranda

Summary: The study found that the expression of CRL4-CRBN complex proteins assessed by immunohistochemistry is associated with the treatment response and prognosis in multiple myeloma patients undergoing immunomodulatory drug therapy. This helps identify patients who are more likely to respond positively to immunomodulatory drug therapy.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Frank G. Rucker, Ling Du, Tamara J. Luck, Axel Benner, Julia Krzykalla, Insa Gathmann, Maria Teresa Voso, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Lynn Savoie, Jorge Sierra, Celine Pallaud, Miguel A. Sanz, Joop H. Jansen, Dietger Niederwieser, Thomas Fischer, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Richard A. Larson, Clara D. Bloomfield, Richard M. Stone, Hartmut Doehner, Christian Thiede, Konstanze Doehner

Summary: In AML, internal tandem duplications of the FLT3 gene are associated with poor prognosis. Specifically, insertion site in TKD1 is correlated with unfavorable prognosis, and treatment with Midostaurin does not improve this condition.

LEUKEMIA (2022)

添加到收藏夹

Article Hematology

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

Aaron T. Gerds, Bart L. Scott, Peter Greenberg, Tara L. Lin, Daniel A. Pollyea, Amit Verma, Monique Dail, Yuning Feng, Cherie Green, Connie Ma, Bruno C. Medeiros, Mark Yan, Kasra Yousefi, William Donnellan

Summary: The preliminary results from this study show that atezolizumab, either as a single agent or in combination with azacitidine, has poor safety and efficacy outcomes in patients with relapsed/refractory or HMA-naive myelodysplastic syndrome (MDS).

BLOOD ADVANCES (2022)

添加到收藏夹

Article Oncology

Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study

Cecilie Velsoe Maeng, Christian Fynbo Christiansen, Kathleen Dori Liu, Peter Kamper, Steffen Christensen, Bruno C. Medeiros, Lene Sofie Granfeldt Ostgard

Summary: This study investigates the risk factors and outcomes of intensive care unit admission for acute leukemia patients. The study found that patients with a higher performance status score were at increased risk of ICU admission, and ICU-admitted patients had a higher mortality rate within the first year.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Oncology

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath

Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Hematology

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Adam D. Cohen, Maria-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel

Summary: The CARTITUDE-2 study evaluated the safety and efficacy of cilta-cel in patients with multiple myeloma who had previously received anti-BCMA treatment. The results showed that cilta-cel induced favorable responses in patients who had exhausted other therapies.

BLOOD (2023)

添加到收藏夹

Article Oncology

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

Adam D. Cohen, Parameswaran Hari, Myo Htut, Jesus G. Berdeja, Saad Z. Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Carolyn C. Jackson, Katharine S. Gries, John M. Fastenau, Satish Valluri, William Deraedt, Muhammad Akram, Rebecca Crawford, Ross Morrison, Lynda Doward, Kate Morgan, Silene ten Seldam, Andrzej Jakubowiak, Sundar Jagannath

Summary: Ciltacabtagene autoleucel (cilta-cel) is a CAR-T cell therapy that has shown efficacy in patients with relapsed/refractory multiple myeloma and improvements in health-related quality of life. Patient perspectives on cilta-cel treatment provide additional context to clinical outcomes and the majority of patients reported that their expectations were met or exceeded.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

添加到收藏夹

Article Oncology

The Dynamics of Financial Toxicity in Multiple

Mark A. Fiala, Alice E. Silberstein, Mark A. Schroeder, Keith E. Stockerl-Goldstein, Ravi Vij

Summary: A study of patients with multiple myeloma found that not having a college degree was the only characteristic associated with financial toxicity. Additionally, 34% of patients reported changes in their financial toxicity status at a subsequent time point.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

添加到收藏夹

Article Medical Laboratory Technology

A Single Reference Interval for Interpreting Serum Free Light Chains across Patients with Varying Renal Function

Vahid Azimi, Michael Slade, Mark Fiala, Julie M. Fortier, Keith Stockerl-Goldstein, John L. Frater, Jonathan R. Brestoff, Ronald Jackups, Mark A. Zaydman

Summary: This study developed two new serum free light chain (sFLC) interpretation methods, based on the sFLC ratio and a novel principal component analysis (PCA) metric, respectively. Compared to the manufacturer's reference interval, both new methods exhibited lower false positive rates and greater robustness to renal function while maintaining equivalent sensitivity for monoclonal gammopathy (MG) diagnosis.

CLINICAL CHEMISTRY (2023)

添加到收藏夹

Article Oncology

Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study

Michael Slade, Mark Fiala, Sarah Kelley, Zachary D. Crees, Mark A. Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Summary: The study validated a new risk score for identifying high-risk patients for relapse within 18 months of diagnosis and compared its predictive ability with other risk stratification systems. The results showed that the new risk score had similar predictive performance as existing systems and further studies are needed to find the optimal approach.

LEUKEMIA RESEARCH (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Keith Stockerl-Goldstein, Sarah M. Larson, Illes Arpad, Giulio A. Milone, Massimo Martino, Patrick Stiff, Douglas Sborov, Denise Pereira, Ivana Micallef, Gemma Moreno-Jimenez, Gabor Mikala, Maria Liz Paciello Coronel, Udo Holtick, John Hiemenz, Muzaffar H. Qazilbash, Nancy Hardy, Tahir Latif, Irene Garcia-Cadenas, Abi Vainstein-Haras, Ella Sorani, Irit Gliko-Kabir, Inbal Goldstein, Debby Ickowicz, Liron Shemesh-Darvish, Shaul Kadosh, Feng Gao, Mark A. Schroeder, Ravi Vij, John F. DiPersio

Summary: Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). Motixafortide combined with G-CSF significantly improves the collection of CD34(+) hematopoietic stem cells compared to G-CSF alone. Motixafortide + G-CSF demonstrates superior efficacy in ASCT.

NATURE MEDICINE (2023)

添加到收藏夹

Article Hematology

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schoenland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Summary: The VITAL trial assessed the efficacy and safety of birtamimab in combination with standard of care in AL amyloidosis patients. Although no significant difference was observed in the overall results, a post hoc analysis showed significant improvement in survival time at month 9 for Mayo stage IV patients treated with birtamimab.

BLOOD (2023)

添加到收藏夹

Article Oncology

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

Myo Htut, Binod Dhakal, Adam D. Cohen, Thomas Martin, Jesus G. Berdeja, Saad Z. Usmani, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, Tzu-min Yeh, Xiaoying Xu, Lida Pacaud, Muhammad Akram, Sundar Jagannath

Summary: This study retrospectively analyzed the efficacy and safety of cilta-cel in patients who had received alloSCT prior to treatment. The results showed that cilta-cel had comparable efficacy and safety profiles in patients with and without prior alloSCT.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

添加到收藏夹

Article Oncology

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei-Ting Hwang, Dan T. Vogl, Adam J. Waxman, Simon F. Lacey, Vanessa E. Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer

Summary: This study conducted a clinical trial of CAR T cells in multiple myeloma patients and found that it can be a safe and effective treatment for the disease. The results demonstrate the relationship between early treatment and CAR T cell reexpansion and durable clinical response.

BLOOD CANCER DISCOVERY (2023)

添加到收藏夹

Article Oncology

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Guillermo Garcia-Manero, Nikolai A. Podoltsev, Megan Othus, John M. Pagel, Jerald P. Radich, Min Fang, David A. Rizzieri, Guido Marcucci, Stephen A. Strickland, Mark R. Litzow, M. Lynn Savoie, Bruno C. Medeiros, Mikkael A. Sekeres, Tara L. Lin, Geoffrey L. Uy, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Richard M. Stone, David Claxton, James Essell, Selina M. Luger, Sanjay R. Mohan, Anna Moseley, Frederick R. Appelbaum, Harry P. Erba

Summary: This study suggests that the use of higher dose cytarabine during induction therapy does not improve outcomes in patients with acute myeloid leukemia.

LEUKEMIA (2023)

添加到收藏夹

Article Hematology

Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality

Lawrence Wayne Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Ramzi Abboud, Peter Westervelt, Camille Abboud, Ravi Vij, Keith Stockerl-Goldstein, Iskra Pusic, Amanda F. Cashen, Mark A. Schroeder

Summary: Letermovir is effective in preventing CMV infection in CMV seropositive recipients. This study provides data on the incidence of csCMVi and overall survival beyond the initial 24 weeks after alloSCT. It also identifies risk factors for CMV-related mortality and suggests the possible need for extended use of letermovir.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.